Clinical trials: Hemostatic Disorders
Multiple Myeloma
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
This Phase I/IIa clinical study is to test safety and anti-tumor activity of BT062 to define the best dose in treating patients with relapsed or refractory multiple myeloma with multiple doses of BT062.
- Trial name
- NCT01001442
- Testing
- BT062
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Blood Loss, Surgical
QStat in Liver Transplant
This study will assess the clinical performance of the Quantra System with the QStat Cartridge in the liver transplant population.
- Trial name
- NCT04114253
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- HemoSonics LLC
Multiple Myeloma
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
The purpose of this study is to determine the efficacy of Lenalidomide/Dexamethasone + Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan.
- Trial name
- NCT02272803
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608)
- Where
- 28 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Autologous Stem Cell Transplantation
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous…
- Trial name
- NCT00396331
- Testing
- G-CSF plus plerixafor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01432353
- Testing
- DFRF4539A
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT01592370
- Testing
- Nivolumab, Ipilimumab, Lirilumab
- Where
- 43 sites in United States, Belgium and 4 more
- Volunteers
- 320 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
The purpose of this study is to determine the best dose of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT01583283
- Testing
- ACY-1215, lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Celgene
Non-Hodgkin's Lymphoma(NHL), Multiple Myeloma
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
To investigate the safety and tolerability of OPB-31121 following repeated oral administration of OPB-31121 in patients Non-Hodgkin's Lymphoma(NHL) or Multiple Myeloma(MM) To determine the potential dose-limiting toxicities and…
- Trial name
- NCT00511082
- Testing
- OPB-31121
- Where
- Hong Kong
- Volunteers
- 7 people
- Sponsor
- Otsuka Beijing Research Institute
Multiple Myeloma
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process.
- Trial name
- NCT05172596
- Testing
- PHE885
- Where
- 36 sites in United States, Australia and 12 more
- Volunteers
- 146 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Hematological Neoplasms
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
The primary aim of this observational study is to collect safety and effectiveness data for bortezomib used at first relapse in a group of multiple myeloma patients who received specific and well defined first line treatments…
- Trial name
- NCT00440479
- Testing
- Bortezomib
- Where
- 9 sites in Netherlands
- Volunteers
- 11 people
- Sponsor
- Janssen-Cilag B.V.
Advanced Cancer, Ovarian Cancer
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced…
- Conditions
- Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT04354246
- Testing
- Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy.
- Where
- 9 sites in United States
- Volunteers
- 94 people
- Sponsor
- Compugen Ltd
Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)
The primary purpose of this study was to determine the recommended dose (RD) of birabresib (MK-8628) /OTX015 for further phase II studies, in participants with acute leukemia (AL) including acute myeloid leukemia (AML; de novo…
- Conditions
- Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma
- Trial name
- NCT01713582
- Testing
- OTX015/Birabresib
- Volunteers
- 141 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Multiple Myeloma
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- CERVINO (NCT06158841)
- Testing
- Etentamig, Carfilzomib, Pomalidomide
- Where
- 166 sites in United States, Australia and 23 more
- Volunteers
- 421 people
- Sponsor
- AbbVie
Hemorrhage, Gastrointestinal Hemorrhage
HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding
This observational study will collect information from adult patients in Japan who are treated with Histoacryl® to stop bleeding from arteries in the chest or abdomen, in order to better understand how well the treatment works…
- Conditions
- Hemorrhage, Gastrointestinal Hemorrhage, Hemoptysis, Postpartum Hemorrhage
- Trial name
- HEAL (NCT07753005)
- Testing
- Embolization therapy
- Where
- 11 sites in Japan
- Volunteers
- 176 people
- Sponsor
- Aesculap AG
Relapsed or Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- BENCH (NCT04939142)
- Testing
- SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
- Where
- 33 sites in China
- Volunteers
- 154 people
- Sponsor
- Antengene Corporation
Multiple Myeloma
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be…
- Trial name
- DREAMM 14 (NCT05064358)
- Testing
- Belantamab mafodotin
- Where
- 77 sites in United States, Argentina and 16 more
- Volunteers
- 177 people
- Sponsor
- GlaxoSmithKline
Myeloma Multiple
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04816526
- Testing
- Descartes 08
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Cartesian Therapeutics
Multiple Myeloma
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
This is an open-label, randomized clinical study with two stages to assess the maximum tolerated dose (MTD), efficacy, and safety of selinexor, lenalidomide, and dexamethasone (SLd) in patients with relapsed/refractory (RR)…
- Trial name
- SLAM (NCT02389543)
- Testing
- Selinexor, Lenalidomide, Dexamethasone
- Sponsor
- Karyopharm Therapeutics Inc
Relapsed or Refractory Multiple Myeloma
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM).
- Trial name
- NCT06375044
- Testing
- SIM0500
- Where
- 16 sites in United States, China
- Volunteers
- 130 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Multiple Myeloma
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent cellular cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate (ADC) which binds specifically to B cell maturation…
- Trial name
- NCT03828292
- Testing
- Belantamab mafodotin, Bortezomib, Dexamethasone
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.